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Abstract
EBNA3C, one of the Epstein-Barr virus (EBV)-encoded latent antigens, is essential for primary B-cell transformation. Cyclin D1,
a key regulator of G1 to S phase progression, is tightly associated and aberrantly expressed in numerous human cancers.
Previously, EBNA3C was shown to bind to Cyclin D1 in vitro along with Cyclin A and Cyclin E. In the present study, we
provide evidence which demonstrates that EBNA3C forms a complex with Cyclin D1 in human cells. Detailed mapping
experiments show that a small N-terminal region which lies between amino acids 130–160 of EBNA3C binds to two different
sites of Cyclin D1- the N-terminal pRb binding domain (residues 1–50), and C-terminal domain (residues 171–240), known to
regulate Cyclin D1 stability. Cyclin D1 is short-lived and ubiquitin-mediated proteasomal degradation has been targeted as a
means of therapeutic intervention. Here, we show that EBNA3C stabilizes Cyclin D1 through inhibition of its poly-
ubiquitination, and also increases its nuclear localization by blocking GSK3b activity. We further show that EBNA3C
enhances the kinase activity of Cyclin D1/CDK6 which enables subsequent ubiquitination and degradation of pRb. EBNA3C
together with Cyclin D1-CDK6 complex also efficiently nullifies the inhibitory effect of pRb on cell growth. Moreover, an sh-
RNA based strategy for knock-down of both cyclin D1 and EBNA3C genes in EBV transformed lymphoblastoid cell lines (LCLs)
shows a significant reduction in cell-growth. Based on these results, we propose that EBNA3C can stabilize as well as
enhance the functional activity of Cyclin D1 thereby facilitating the G1-S transition in EBV transformed lymphoblastoid cell
lines.
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Introduction
Epstein–Barr virus (EBV) is a B-lymphotropic human herpes
virus that persists indefinitely in latently infected B-cells. EBV
infection occurs early in life for most people and is associated with
a broad spectrum of benign and malignant diseases including
Burkitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC),
Hodgkin’s disease (HD) and lymphomas associated with im-
muno-compromised individuals, including AIDS patients and
post-transplant patients receiving immune-suppressive therapy [1].
EBV infection in B-cell leads to aberrant cell division and under
favorable conditions the infected B-cells will continue to proliferate
indefinitely, resulting in development of immortalized lympho-
blastoid cell lines (LCLs) [1,2].
One of the most noteworthy EBV-host cell interactions is the
establishment of viral latency. There are three major types of
latency, each having its own distinct viral-gene expression pattern
[1,2]. Type I latency is usually noticed in BL tumors with
predominant expression of EBV encoded nuclear antigen 1
(EBNA-1) [1,2]. Type II latency is demonstrated in NPC and
HD, where EBNA-1, latent membrane protein 1 (LMP-1), LMP-
2A and -2B proteins are significantly detected [1,2]. Type III
latency, also termed as ‘growth program’ [1,2] is typically seen in
LCLs expressing six latent nuclear proteins (EBNA-1, -2, -3A, -3B,
-3C, and -LP), three latent membrane proteins (LMP-1, -2A, and -
2B), and the viral RNAs which includes the EBERs and BARTs
(33, 62).
Molecular genetics analyses have demonstrated that at least six
EBV latent genes (EBNA-1, -2, -3A, -3C, -LP, and LMP-1) are
essential for in vitro immortalization [1,2], indicating that a
complex cascade of molecular events is required to surpass normal
growth controls. One scenario which accounts for EBV-mediated
B-cell immortalization is modulation of critical positive and/or
negative regulators of cell-cycle progression, such as cyclins, cyclin-
dependent kinases (CDKs), cyclin-dependent kinase inhibitor
proteins (CDKIs), tumor-suppressors and apoptosis related
proteins which includes p53 and pRb [3].
EBNA3C, one of the essential EBV latent antigens, has been
shown to function both as a transcriptional activator and a
repressor [4,5,6]. It has also been shown to interact with numerous
transcription modifiers, including c-Myc [4], prothymosin a [7],
histone deacetylases [8], CtBP [9], NM23-H1 [10], DP103 [11],
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Skp2 [12], p300 [13] and p53 [14] which contributes to EBV
induced transformation mediated by EBNA3C. In addition, a
large body of evidence indicates that EBNA3C can also deregulate
the cell-cycle machinery through direct protein-protein interaction
and post-translational modification of important cell-cycle regula-
tory proteins, including Cyclin A [15,16], pRb [17], p53 [14],
Mdm2 [18], and Chk2 [19].
So far, studies probing EBNA3C functions provide perhaps the
best link between latent EBV infection and the pRb regulated
checkpoint which controls the G1-S phase transition [20,21].
EBNA3C was previously shown to indirectly target pRb regulated
pathways [15,20]. EBNA3C also activates E2F-dependent pro-
moters and can induce foci formation in colony formation assays
[20]. Additionally, EBNA3C overcomes the ability of the CDK
inhibitor - p16
INK4A to block transformation and noticeably drives
serum-starved cells through the G1-S restriction point [20,21].
More recently, we have shown that EBNA3C directly targets pRb
and may indirectly target the pRb regulated checkpoint by
associating with Cyclin A as well as Cyclin D1 known to be
important in phophorylating pRb [15,16]. Despite this body of
evidence, a clear molecular link between these molecules
responsible for disrupting the G1-S phase blockage and EBNA3C
is yet to be demonstrated.
Cell-cycle progression is dependent on the activity of cyclins, a
family of proteins whose levels oscillate in synchrony with cell-
cycle progression, and its functional partner CDKs [22]. Cyclin D
(D1, D2 and D3) is expressed in the mid-G1 phase in the
mammalian cell-cycle [23]. Among the D-type cyclins, Cyclin D1
is the most ubiquitous and is frequently over-expressed in
numerous human malignancies [24,25]. Cyclin D1 over-expres-
sion is often associated with increased gene expression due to gene
amplification or post-translational modification [26]. Accumula-
tion of Cyclin D1 in cancer can result in overcoming ubiquitin-
mediated degradation through several distinct mechanisms [26].
Cyclin D1, together with its catalytic partners CDK4 or CDK6,
promotes G1-S-phase transition via phosphorylation of pRb and
disrupting the pRb-E2F1 repressor complex [23]. These functions
of Cyclin D1 ensure efficient initiation of S phase [26,27]. During
late G1 and S phases, Cyclin D1 is phosphorylated on Thr-286 by
GSK3b, which triggers nuclear export and proteasomal degrada-
tion through E3 ubiquitin ligase, SCF
FBX4-aB crystallin [26]. Thus,
subversion of either of these functions may result in unrestrained
cell proliferation and oncogenesis.
The cyclin D1 gene is located on chromosome 11q13, close to the
bcl-1 locus, and is considered to be a proto-oncogene with evidence
indicating that its derangement contributes to the development of
tumors [28]. Mantle cell lymphomas have been reported to over-
express Cyclin D1 due to a characteristic genetic translocation
[28]. In addition, patients with tumors over-expressing Cyclin D1
have been shown to have a particularly poor prognosis [25,29];
however, over-expression of Cyclin D1 has been demonstrated for
a vast series of human malignancies including breast cancers,
esophageal cancers and pancreatic cancers [25,30]. Over-
expression of Cyclin D1, regardless of its gene alteration, caused
abnormal cell proliferation, resulting in oncogenesis [22,23,31].
cyclin D2, considered also as a proto-oncogene, is located on
chromosome 12p13, and unlike Cyclin D1, Cyclin D2 has been
reported to be expressed normally in B-lymphocytes [32].
Interestingly, it has been observed that ectopic over-expression
of Cyclin D2 efficiently blocks cell-cycle progression [33],
suggesting an alternate role for Cyclin D2 in promoting exit from
the cell-cycle and maintaining cells in a non-proliferative state.
These observations suggest that D-type cyclins may have different
roles depending on their levels of expression and cell type, which
may also be independent of CDK activity. Reports have shown
that immortalization of primary B-lymphocytes by EBV is
accompanied by transcriptional activation of cyclin D2 gene but
not cyclin D1 [32,34]. However, Cyclin D1 protein has been shown
to be significantly expressed in a number of EBV positive LCLs
[35,36] or EBV positive SCID mice lymphomas [37]. Surprisingly,
these studies did not directly set out to explore the contribution of
Cyclin D1 in EBV-mediated B-cell oncogenesis.
A previous study from our lab showed an in vitro interaction
between the EBV encoded antigen EBNA3C and Cyclin D1 [16].
The experiments described in this current study explore the
consequences of this interaction in terms of EBV mediated
transformation of primary B-cells as well as growth maintenance of
LCLs. We now show that EBNA3C stabilizes as well as enhances
the kinase activity of the Cyclin D1/CDK6 complex, and the
nuclear localization of Cyclin D1 to bypass the G1 restriction
point. Importantly, this study provides the first evidence to show
that the essential EBV latent antigen EBNA3C targets Cyclin D1,
which is different from previous reports, and describes a potential
fundamental mechanism by which EBV deregulates the mamma-
lian cell-cycle in EBV-associated human cancers by facilitating the
G1-S transition.
Materials and Methods
Plasmids, antibodies, cell lines and transfection
Myc, flag, GFP and GST tagged EBNA3C vectors have been
described previously [14,18]. pcDNA3-HA-Ub was kindly pro-
vided by George Mosialos (Aristotle University of Thessaloniki,
Thessaloniki, Greece). Vectors pcDNA3-Cyclin D1, pcDNA3-1x
flag-Cyclin D2 and pcDNA3-1x flag-Cyclin D3 were provided by
Alan Diehl (University of Pennsylvania School of Medicine,
Philadelphia) and used to generate pA3F-Cyclin D by cloning
PCR amplified DNA into pA3F vector [4]. GST Cyclin D1
vectors were cloned by inserting PCR amplified DNA into pGEX-
2TK vector (GE Healthcare Biosciences, Pittsburgh, PA). pGEX-
Cyclin D1 (286A) was generated by PCR using pA3F-Cyclin D1 as
template. Sh-RNA vector, pGIPZ (Open Biosystems, Inc.
Huntsville, AL) and lentiviral packaging vectors were described
[38]. CDK6 cDNA cloned into pA3F vector was derived from
HEK 293 cell RNA that was purified with TRIzol reagent and
reverse transcribed with Superscript II (Invitrogen, Inc., Carlsbad,
CA). Mouse antibodies to Cyclin D1 (DSC-6) and Sp1 (1C6), and
rabbit antibody to Ub (FL-76) were from Santa Cruz Biotechnol-
ogy, Inc (Santa Cruz, CA). Rabbit antibodies to Cyclin D2 and D3
were kindly provided by Alan Diehl (University of Pennsylvania
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epitope (M2) was from Sigma-Aldrich Corp. (St. Louis, MO) and
to GAPDH was from US-Biological Corp. (Swampscott, MA).
Antibodies to HA-epitope (12CA5) or Myc-epitope (9E10) were
prepared from cell culture supernatants as described [14,18].
Mouse (A10) or rabbit antibody to EBNA3C were described
[14,18].
HEK 293, 293T and Saos-2 (p53
-/- pRb
-/-)c e l l sw e r eo b t a i n e d
from Jon Aster (Brigham and Women’s Hospital, Boston, MA, USA).
Saos-2 and U2OS are human osteosarcoma cell line [39]. HEK 293,
HEK 293T, U2OS, and Saos-2 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM; HyClone, Logan, UT) supple-
mented with 10% fetal bovine serum (FBS; HyClone, Logan, UT),
50 U/ml penicillin (HyClone, Logan, UT), 50 mg/ml streptomycin
(HyClone, Logan, UT) and 2 mM L-glutamine (HyClone, Logan,
UT). BL lines BJAB, Ramos, BL41 and B95.8 infected BL41 (BL41/
B95.8) were kindly provided by Elliott Kieff (Harvard Medical
School, Boston, MA). MutuI, MutuIII were provided by Yan Yuan
(School of Dental Medicine, University of Pennsylvania, Philadel-
phia, PA). These BL lines and LCL1 and LCL2 were maintained in
RPMI 1640 (HyClone, Logan, UT) supplemented as described
above. EBNA3C expressing BJAB lines were described [14,18].
Unless otherwise stated all cultures were incubated at 37uCi na
humidified environment supplemented with 5% CO2.
Adherent cells were transfected by electroporation with a Bio-
Rad Gene Pulser II electroporator as described [14,18].
Infection of PBMCs with BAC GFP-EBV
Peripheral blood mononuclear cells (PBMC) from healthy
donors were obtained from University of Pennsylvania Immunol-
ogy Core. As described [40], approximately 10 million PBMC
were mixed with virus supernatant in 1 ml of RPMI 1640 with
10% FBS for 4 hr at 37uC. Cells were centrifuged for 5 min
at500 g, discarded the supernatant, pelleted cells and resuspended
in 2 ml of complete RPMI 1640 medium in 6 well plates. EBV
GFP expression visualized by fluorescence microscopy was used to
quantify infection. The protein and mRNA level of the infected
cells was detected after 3 days of post-infection.
Immunoprecipitation (IP) and western blotting (WB)
Transfected cells were harvested, washed with ice cold PBS and
lysed in 0.5 ml ice cold RIPA buffer [1% Nonidet P-40 (NP-40),
10 mM Tris pH 8.0, 2 mM EDTA, 150 mM NaCl, supplemented
with protease inhibitors (1 mM phenylmethylsulphonyl fluoride
(PMSF), 1 mg/ml each aprotinin, pepstatin and leupeptin]. Lysates
were precleared with normal mouse serum plus 30 mL of Protein
A/G Sepharose (1 h, 4uC). 5% of the precleared lysate was saved
for input control and the protein of interest was captured by
rotating the remaining lysate with 1 mg of specific antibody
overnight at 4uC. Immuno-complexes were captured with 30 mlo f
a 1:1 mixture of Protein-A and Protein-G Sepharose beads,
pelleted and washed 5X with ice cold RIPA buffer.
For western blots, input lysates and IP complexes were boiled in
laemmli buffer [41], fractionated by SDS-PAGE and transferred
to a 0.45 mm nitrocellulose membrane. The membranes were then
probed with specific antibodies followed by incubation with
appropriate infrared-tagged secondary antibodies and viewed on
an Odyssey imager. Image analysis and quantification measure-
ments were performed using the Odyssey Infrared Imaging System
application software (LiCor Inc., Lincoln, NE).
Purification of GST fusion proteins and pull-down assays
Escherichia coli BL21 cells were transformed with plasmids for
each glutathione S-transferase (GST) fusion protein and protein
complexes containing the tagged proteins were purified essentially
as described before [14,18].
For in vitro binding experiments, GST fusion proteins were
incubated with cell lystaes or
35S-labeled in vitro-translated protein
in binding buffer (1x phosphate-buffered saline [PBS], 0.1% NP-
40, 0.5 mM dithiothreitol [DTT], 10% glycerol, supplemented
with protease inhibitors). In vitro translation was done with the
TNT T7 Quick Coupled Transcription/Translation System
(Promega Inc., Madison, WI) according to the manufacturer’s
instructions.
Immunofluorescence
Cells were immuno-stained as described [18] with few
modifications. Briefly, U2OS cells plated on coverslips were
transfected with expression vectors as indicated, using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA) according to manufacturer’s
protocol. After 36 h of transfection cells were fixed. B-cells were
air-dried and subsequently fixed. Transiently expressed flag-tagged
Cyclin D1 was detected using M2-antibody, and GFP-EBNA3C
was detected by GFP fluorescence. In B-cells, endogenously
expressed Cyclin D1 and EBNA3C proteins were detected using
specific antibody. The slides were examined with a Fluoview
FV300 confocal microscope (Olympus Inc., Melville, NY).
Real time quantitative PCR
Total RNA was isolated by using TRIzol reagent according to the
instructions of the manufacturer (Invitrogen, Inc., Carlsbad, CA).
cDNA was made by using a Superscript II reverse transcriptase kit
(Invitrogen, Inc., Carlsbad, CA) according to the instructions of the
manufacturer. The primers were for cyclin D1, 59-TGCCCTCT-
GTGCCACAGATG-39,a n d5 9-TCTGGAGAGGAAGCGTGTG-
A-39,f o rcyclin D2 59-TGCTCTGTGTGCCACCGACTT-39,a n d
59-CAGCTCAGTCAGGGCATCACAA-39,f o rcyclin D3 59-TTT-
GCCATGTACCCGCCATCCA-39 and 59-CCCGCAGGCAGT-
CCACTTCA-39,a n df o rGAPDH 59-TGCACCACCAACTGCT-
TAG-39 and 59-GATGCAGGGATGATGTTC-39. Quantitative
real-time PCR analysis was done as described [18] in triplicate.
In vivo poly-ubiquitination assay
15610
6 HEK 293T cells were transfected by electroporation
with DNA vectors expressing a specific protein. Cells were
incubated for 36 h and pretreated for an additional 6 h with
20 mM MG132 (Enzo Life Sciences International, Inc., Plymouth
Meeting, PA) before harvesting. Proteins were immunoprecipitat-
ed with specific antibodies and resolved by SDS-PAGE. The
extent of ubiquitination of immunoprecipitated complexes were
detected by HA-specific antibody (12CA5) against HA-Ub tagged
proteins.
Subcellular fractionation assay
15610
6 HEK 293 cells were transfected with expression
plasmids. After 36 h cells were PBS washed and resuspended into
hypotonic buffer [5 mM Pipes (KOH) pH 8.0, 85 mM KCl, 0.5%
NP-40 supplemented with protease inhibitors). After 10-min
incubation on ice, cells were homogenized with 20 strokes in a
Dounce homogenizer, nuclei were pelleted (2300 g for 5 min) and
the cytosolic material was collected. Nuclear pellets were PBS
washed, resuspended in nuclear lysis buffer (50 mM Tris, pH 8.0,
2 mM EDTA, 150 mM NaCl, 1% NP-40, and protease
inhibitors), lysed by vortexing periodically for 1 h. Soluble nuclear
fraction was separated by centrifugation at 21000 g for 10 min.
Total protein was measured by Bradford protein assay and 50 mg
of total protein was resolved by SDS-PAGE. The efficiency of
EBNA3C Enhances Cyclin D1 Activity
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blot against nuclear transcription factor Sp1 and cytoplasmic
protein GAPDH.
In vitro kinase assay
15610
6 HEK 293T cells were transfected with plasmids
expressing flag-Cyclin D1 (5 mg), flag-CDK6 (5 mg) and increasing
amount of myc-EBNA3C (0, 5, 10, 20 mg). For GSK-3b kinase
assay cells were transfected with DNA vectors that express myc-
tagged GSK-3b (10 mg) and flag-tagged EBNA3C (20 mg). Cells
were harvested and protein complexes were immunoprecipitated
(IP) using either M2 (for cyclin D1) or 9E10 ascites fluid (for GSK-
3b). IP complexes were then washed with buffer A (25 mM Tris
[pH 7.5], 70 mM NaCl, 10 mM MgCl2, 1 mM EGTA, 1 mM
DTT, plus protease and phosphatase inhibitors) and incubated in
30 ml of kinase buffer B (buffer A plus 10 mM cold ATP, and
0.2 mCi of [c-
32P]-ATP/ml) supplemented with either 4 mgo f
histone H1 (Upstate Biotechnology, Inc., Lake Placid, N.Y.) or
bacterially purified GST-pRb (residues 792-928) for 30 min at
30uC. The reaction was stopped by adding 2X laemmli buffer [41]
and heating to 95uC for 10 min. Labeled proteins were resolved by
12% SDS-PAGE. Band quantitation was performed using the
ImageQuant software (GE Healthcare Biosciences, Pittsburgh, PA).
Stability assay
Cells were transiently transfected using electroporation with
plasmids as indicated in the text. After 36 hours transfection, cells
were treated with 40 mg/ml cyclohexamide (CalBiochem, Gibbs-
town, NJ) and lysates were subjected to immunoblot analyses.
Band intensities were quantitated using Odyssey 3.0 software
provided by Odyssey imager (LiCor Inc., Lincoln, NE).
Lentiviral shRNA expressing constructs
Short-hairpin oligonucleotides directed against EBNA3C were
designed (Dharmacon Research, Chicago, IL). The sense strand of the
EBNA3C-shRNA sequence is 59-tcgagtgctgttgacagtgagcgaCCATA-
TACCGCAAGGAATAtagtgaagccacagatgtaTATTCCTTGCGGT-
ATATGGgtgcctactgcctcggaa-39. The sense strand of cyclin D1 sh-
RNA sequence is 59-tcgagtgctgttgacagtgagcgaCAAACAGATCATC-
CGCAAAtagtgaagccacagatgtaTTTGCGGATGATCTGTTTgtgcc-
tactgcctcggaa-39 [42]. Upper-case letters indicate 19-nucleotide (nt)
either EBNA3C or cyclin D1 target sequences respectively and
lowercase letters indicate hairpin and sequences necessary for the
directional cloning into pGIPZ (Open Biosystems, Inc. Huntsville,
AL). Single-stranded EBNA3C and cyclin D1 oligonucleotides were
first annealedandthen clonedintothe XhoIandMlu Irestriction sites
of pGIPZ vector. The fidelity ofc l o n e dd o u b l e - s t r a n dD N Aw a s
confirmed by DNA sequencing. In parallel, a commonly available
control shRNA sequence (Dharmacon Research, Chicago, IL): (59-
TCTCGCTTGGGCGAGAGTAAG-39) that lacks complementary
sequences in the human genome was also cloned into pGIPZ vector.
Lentivirus production and transduction of EBV-
transformed B-cells
Lentivirus production and transduction of EBV-transformed B-
cells (LCLs) were essentially carried out as previously described
[38].
Proliferation assay
Saos-2 (p53
-/- pRb
-/-) were transfected using Ca3(PO4)2 method
as described [38]. After 24 h transfection, cells were selected using
DMEM supplemented with 1000 mg/ml G418; Invitrogen). After
a 2-week selection, 5610
6 cells were harvested, lysed in RIPA
buffer and subjected for immunoblot analyses. Approximately
0.1610
6 cells from each set of samples were plated into each well
of the 6-well plates and cultured for 6 days. Viable cells from each
well were counted by trypan blue exclusion method daily using a
Bio-Rad TC10 Automated cell counter.
For LCLs, approximately 1610
6 cells were plated into each well
of the 6-well plates and cultured at 37uC in complete RPMI
medium. Cells were counted similarly for 20 days. Both
experiments were performed in duplicate and were repeated two
times.
Colony formation assay
5610
6 Saos-2 (pRb
-/-) cells were transfected as described [38]
and cultured in DMEM supplemented with 1 mg/ml G418
(Invitrogen, Inc., Carlsbad, CA). After a 2-week selection, cells
were fixed on the plates with 4% formaldehyde and stained with
0.1% crystal violet (Sigma-Aldrich Corp., St. Louis, MO). The
area of the colonies (pixels) in each dish was calculated by Image J
software (Adobe Inc., San Jose, CA). The data are shown as the
average of three independent experiments.
Cell-cycle analysis
For serum starvation experiments, the culture medium was
replaced with RPMI 1640 and 0.1% FBS for 12 h. Cells were PBS
washed, fixed in cold 70% ethanol for 30 min at 20uC, PBS
washed and stained 2 h in buffer containing 50 mg/ml propidium
iodide, 10 mM Tris pH 7.5, and 500 U/ml RNAseA in dark. PBS
washed cells were analyzed for cell-cycle profile by FACS Calibur
system and Cellquest software (Becton-Dickinson Inc., San Jose,
CA).
Results
EBV infection leads to induction of Cyclin D1
In order to determine whether EBV infection alters Cyclin D
expression, approximately 10610
6 human resting peripheral
blood mononuclear cells (PBMC) were infected by BAC GFP-
EBV as previously described [40] for 4 h and western blot analysis
was performed on samples collected 3 days after infection. The
results showed that EBV infection leads to a significant induction
of all three Cyclin D protein levels 3 days post-infection, with no
preference for any particular D-type cyclins (Fig. 1A). Similarly,
western blot results of Burkitt’s lymphoma (BL) cell line BL41 and
BL41 infected with wild-type EBV strain B95.8 (BL41/B95.8) also
showed elevated levels of Cyclin Ds with Cyclin D1 expression
more dramatically changed compared to other Cyclin Ds (Fig. 1B).
Since Cyclin D1 expression was induced significantly after EBV
infection in both PBMC and BL cell line, we next wanted to
determine if the induction was related to a specific EBV latent
protein expressed during type III latency. The results showed that
the levels of both Cyclin D1 and Cyclin D2 proteins were induced
in type III latency BL cell line MutuIII compared to latency I
expressing MutuI BL cell line (Fig. 1C). These results differ with
previously published observations which suggested that B-cells
infected with EBV do not express Cyclin D1 [43,44,45]. However,
in agreement with previously published results [32], our real-time
PCR data showed that EBV infection led to a significant increase
of cyclin D2 mRNA level in LCLs (LCL1 and LCL2) when
compared to EBV negative BL cells (BJAB and Ramos) whereas,
there was little or no detectable change for cyclin D1 mRNA
(Fig. 1F). Real-time PCR data obtained from two other matched
sets of cell lines BL41 – BL41/B95.8 and MutuI – MutuIII also
showed similar results as above (Fig. 1G and 1H, respectively).
These results suggest that D-type cyclins are regulated through
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effects on Cyclin D2 are at the level of its transcript stability
whereas the effects on Cyclin D1 or D3 seem to be post-
translational.
EBNA3C expression leads to stabilization of Cyclin D1
To elucidate the effects of the EBV encoded essential nuclear
antigen, EBNA3C on Cyclin D1, BL lines BJAB and E3C #7, a
BJAB stably expressing EBNA3C were analyzed. The western blot
results showed a significant increase in Cyclin D1 protein
expression among D-type Cyclins in E3C #7 cells compared to
the BJAB control cells and smaller changes in Cyclin D2 and D3
(Fig. 1D). The effect of EBNA3C on Cyclin D1 steady-state levels
was not due to changes in the transcription as EBNA3C expression
did not alter the level of cyclin D1 mRNAs in these cells as seen
above (Fig. 1I). To further verify the role of EBNA3C on Cyclin
D1 protein accumulation, we determined the levels of Cyclin Ds in
a lymphoblastoid cell line with the EBNA3C mRNA specifically
targeted by short-hairpin RNA (Sh-E3C). The western blot data
showed that the expression level of Cyclin D1 in the LCLs stably
knocked-down for EBNA3C (Sh-E3C) was significantly dimin-
ished as compared to the control cell line (Sh-Control) (Fig. 1E),
Figure 1. EBV nuclear antigen EBNA3C stabilizes Cyclin D1 protein level. A) 10 million human peripheral blood mononuclear cells (PBMC)
were infected by BAC GFP-EBV for 4 h. At 3-days post-infection cells were lysed in RIPA buffer and western blots of endogenous proteins were
probed with the indicated antibodies. B-E) 20 million cells of (B) Burkitt’s lymphoma (BL) cell line BL41 and BL41 cells infected with wild-type EBV
strain B95.8 (BL41/B95.8); (C) type I and III latency BL cell lines - MutuI cells (latency I gene expression program) and MutuIII cells (latency III gene
expression program); (D) BJAB cells and BJAB cells stably expressing EBNA3C (BJAB_E3C#7); (E) EBNA3C and cyclin D1 knock-down LCL1 cells
(LCL1_Sh-E3C and LCL1_Sh-CyD1 respectively) were harvested and total cell proteins were subjected to Western blot (WB) analysis using indicated
antibodies. F-I) Total RNA was isolated from cells F) BJAB, Ramos, LCL1 and LCL2; G) BL41 and BL41/B95.8; H) MutuI and MutuIII; I) BJAB and BJAB
E3C3 7 and were individually subjected to quantitative real-time PCR analysis for detecting cyclin D1, D2 and D3 transcript levels. Each sample was
tested in triplicate and data obtained from three independent experiments were expressed as the difference of the quantity of specific transcripts to
the quantity of GAPDH transcript as control. The fold change in expression of each cyclin D mRNA relative to GAPDH was calculated based on the
threshold cycle (Ct) as 2
- D(DCt), where DCt = Cttarget –C t GAPDH and D(DCt) = DCttest sample - DCtcontrol sample. J) HEK 293 cells were transfected with an
increasing amount (0, 2, 5, 20 mg) of EBNA3C expressing construct and western blot analysis was performed to detect EBNA3C, Cyclin D1 and GAPDH.
K) HEK 293 cells were co-transfected with flag-Cyclin D1 and either vector control (lanes 1 and 3) or myc-EBNA3C (lanes 2 and 4). At 36 h
posttransfection, samples were treated with either 40 mM MG132 (+ lanes) or DMSO (- lanes) for 6 h and resolved by 10% SDS-PAGE and probed with
the indicated antibodies. L) HEK 293 cells were similarly transfected with expression plasmids for flag-tagged both Cyclin D1 and CDK6 and myc-
tagged EBNA3C as indicated. At 36 h post-transfection, cells were treated with 40 mg/ml cyclohexamide (CHX) for indicated lengths of time. 10% of
the lysate from each sample were resolved by 10% SDS-PAGE. GAPDH blot was done for loading control. Western blotting was done by stripping and
reprobing the same membrane. Protein bands were quantified using Odyssey imager software as indicated either as arbitrary numerical values at the
bottom of gel (A-E) or as bar diagrams (J-L) based on GAPDH loading control.
doi:10.1371/journal.ppat.1001275.g001
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(Fig. 1E). These results indicate that EBNA3C can contribute to
Cyclin D1 accumulation in latently infected EBV positive cells.
To demonstrate that EBNA3C can stabilize Cyclin D1 protein
levels, HEK 293 cells were transfected with an increasing amount
of an expression construct expressing EBNA3C and tested for
endogenous Cyclin D1 protein level. The results showed that
EBNA3C stabilizes Cyclin D1 protein expression in a dose
dependent manner (Fig. 1J).
We earlier determined that EBNA3C plays a critical role in
modulating the ubiquitin (Ub)-proteasome machinery [12,17,18].
Therefore, to investigate whether the increase of Cyclin D1 levels
was because of the inhibition of Ub-proteasome mediated
destabilization by EBNA3C, transiently co-transfected cells were
treated with the proteasome inhibitor, MG132. The results
showed that both the treatment with MG132, and presence of
EBNA3C led to a significant accumulation (six fold) of Cyclin D1
when compared to mock treatment or vector control (Fig. 1K).
Therefore the increased levels of Cyclin D1 observed in the
presence of EBNA3C and MG132 is a result of stabilization of
Cyclin D1 likely by EBNA3C inhibition of the Ub-proteasome
degradation system. Importantly, both CDK6 and EBNA3C levels
were not altered by MG132 (Fig. 1K).
To directly determine EBNA3C stabilization of Cyclin D1,
HEK 293 cells were transfected with flag-Cyclin D1, flag-CDK6,
and EBNA3C expression vectors. Thirty-six hours later, cells were
treated with protein synthesis inhibitor cycloheximide, and
samples were collected at 0, 1, and 2 hours. Western blots probed
with flag antibody showed that the stability of Cyclin D1 protein
was significantly enhanced by EBNA3C co-expression, whereas in
the absence of EBNA3C, Cyclin D1 was degraded to near
completion by 2-h after addition of CHX (Fig. 1L, grey bar).
Cyclin D1 half life was determined to be 2 h in EBNA3C
expressing cells; however, it shortened noticeably to less than 1 h
when Cyclin D1 was expressed alone (Fig. 1L, bar diagram). The
results also indicated that both EBNA3C and CDK6 were notably
stable throughout the experimental period of time and had no sign
of protein degradation (Fig. 1L, CDK6 indicated as black bar).
Overall, the results of these experiments suggest EBNA3C can
stabilize Cyclin D1 by regulating its targeted degradation likely
through the Ub-proteasome degradation system.
EBNA3C stabilizes Cyclin D1 via inhibiting its poly-
ubiquitination
Recently we have shown that ectopic expression of EBNA3C
leads to stabilization of an important cellular oncoprotein, Mdm2
by inhibiting its poly-ubiquitination [18]. The increased stability of
Cyclin D1 in the presence of EBNA3C, prompted us to examine
whether EBNA3C similarly inhibits poly-ubiquitination of Cyclin
D1 and so enhances its stability. To explore this possibility, three
cell lines were selected, the EBV negative cell line BJAB, BJAB
stably expressing EBNA3C (E3C #7) and an EBV positive
lymphoblastoid cell line (LCL2). Immnuprecipitation using specific
antibody against Cyclin D1 resulted in formation of high
molecular weight species of Cyclin D1 migrating at a slower rate
in BJAB cells while in BJAB cells stably expressing EBNA3C or in
LCL2 significantly less of these high molecular weight bands were
observed (Fig. 2A). Re-probing of the same membrane with Ub
specific antibody showed a similar pattern (Fig. 2A). This result
indicates that the activity responsible for the change in Cyclin D1
bands is present in EBV positive cells (LCL2) and EBNA3C
expressing cell line (E3C #7) when compared to the EBV negative
BJAB cells.
To directly address this phenomenon, an ubiquitination
experiment was set up, where HEK 293T cells were transiently
co-transfected with expression constructs for HA-Ub, flag-Cyclin
D1 and myc-EBNA3C and the ubiquitination of the Cyclin D1
was assessed by immunoprecipitation followed by Western blotting
(Fig. 2B). The result demonstrated a significant and reproducible
reduction in Cyclin D1 poly-ubiquitination level in EBNA3C
expressing cells (Fig. 2B). Similar experiments were performed
separately using two different cyclins, Cyclin A and Cyclin E to
determine if this effect was specific for Cyclin D1. However,
neither Cyclin A nor Cyclin E poly-ubiquitination levels were
reduced in the presence of EBNA3C (Fig. 2C and 2D). To
determine whether the poly-ubiquitination level of the other D-
type cyclins was also affected in the presence of EBNA3C, we
tested flag-tagged Cyclin D2 and D3 for ubiquitination in the
absence and presence of EBNA3C. Importantly, poly-ubiquitina-
tion of both Cyclin D2 and D3 was efficiently inhibited in the
presence of EBNA3C (Fig. 2E). This result indicates that EBNA3C
can profoundly affect the poly-ubiquitination of all Cyclin Ds and
thus enhance their stability.
EBNA3C forms a complex with Cyclin D1 in human cells
We have shown earlier that EBNA3C interacts with Cyclin D1
in vitro along with other cyclins including Cyclin A and Cyclin E
[16]. In order to determine whether EBNA3C forms a complex
with Cyclin D1 in cells to enhance its stability, we performed
binding assays using co-IP experiments. HEK 293T cells were co-
transfected with expression constructs for myc-EBNA3C and flag-
Cyclin D1. The results showed that ectopically expressed
EBNA3C associated with Cyclin D1 in cells (Fig. 3A and 3B).
To further determine whether this binding occurred under
endogenous settings, Cyclin D1 was immunoprecipitated from
EBV negative cell line, BJAB and two EBV transformed
lymphoblastoid cell lines, LCL1 and LCL2 expressing EBNA3C.
EBNA3C was detected by Western blot analysis using A10, an
EBNA3C specific monoclonal antibody and showed efficient co-
immunoprecipitation (Fig. 3C). In a separate experimental setting,
Cyclin D1 was immunoprecipitated from BJAB cells and BJAB
cells stably expressing EBNA3C (E3C#10). Similarly co-IP of
EBNA3C was demonstrated using the A10 antibody (Fig. 3D). To
further corroborate the association in human cells, a GST-
pulldown experiment was conducted; where bacterially expressed
GST-Cyclin D1 was incubated with cell lysates prepared from
either BJAB cells or BJAB cells stably expressing EBNA3C
(E3C#7 and E3C#10). EBNA3C was seen to strongly associate
with GST-Cyclin D1 but not with the GST control (Fig. 3E).
Coomassie staining of a parallel gel showed the amount of GST
and GST-Cyclin D1 proteins used in the binding assay (Fig. 3E,
right panel). Analysis of the data from the ectopic expression
system as well as cell lines endogenously expressing Cyclin D1 and
EBNA3C at physiological levels strongly demonstrated an
association between Cyclin D1 and EBNA3C in human cells.
A small N-terminal region of EBNA3C binds to two
different sites of Cyclin D1
We have previously shown that a small N-terminal region of
EBNA3C (residues 130-160) binds to Cyclin D1 in vitro [16]. To
map the domain of EBNA3C that interacts with Cyclin D1, HEK
293T cells were transfected with expression constructs for flag-
Cyclin D1 and either full-length EBNA3C (residues 1-992),
EBNA3C residues 1-365, EBNA3C residues 366–620, or
EBNA3C residues 621-992. All EBNA3C expression constructs
were fused in frame with a myc epitope tag at the C-terminus of
the protein. As expected, the results showed that Cyclin D1 co-
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N-terminal domain of EBNA3C (residues 1–365) (Fig 4A, left-
middle panel, lanes 2 and 3, respectively) whereas no co-IP was
detected with vector control or other truncated versions of
EBNA3C (Fig 4A, left-middle panel, lanes 1, 4 and 5). To further
corroborate the binding data, an in vitro GST-pulldown experi-
ment was performed using in vitro translated
35S-radiolabeled
fragments of EBNA3C (residues 1–100, 1–129, 1–159 and 1–200)
within the N-terminal domain. In vitro precipitation experiments
with bacterially expressed GST-Cyclin D1 showed strong
association with residues 1–159 and 1-200 of EBNA3C (Fig. 4B,
bottom panel, lanes 3 and 4, respectively), but not with EBNA3C
residues 1–100 or 1–129 (Fig. 4B, bottom panel, lanes 1 and 2,
respectively). All fragments of EBNA3C failed to interact with the
GST control, indicating that the observed binding was specific for
Cyclin D1 (Fig. 4B, middle panel, lanes 1 to 4).
In an attempt to gain insights into the functionality of the
association between Cyclin D1 and EBNA3C, a series of N- and
C-terminal deletion mutants of Cyclin D1 (residues 1–50, 40–170,
171–260 and 241–295) were designed according to their domain
distribution [46,47] and tested for their ability to bind EBNA3C
using in vitro binding experiments. The results of the GST-
pulldown assay clearly showed that full-length Cyclin D1, the N-
terminal pRb binding region (residues 1-50) and the C-terminal
Figure 2. EBNA3C stabilizes Cyclin D1 through inhibiting its poly-ubiquitination. A) 50 million EBV negative BJAB cells, BJAB cells stably
expressing EBNA3C (BJAB_E3C#7) and an EBV transformed cell, LCL2 were harvested after 6h incubation with proteasome inhibitor MG132 (20 mM).
Cells were lysed and Cyclin D1 was immunoprecipitated (IP). Samples were resolved by 10% SDS-PAGE. Western blotting (WB) was done by stripping
and reprobing the same membrane. B-E) 15 million HEK 293T cells were transiently transfected with different combinations of expression plasmids as
indicated. Cells were harvested at 36h, and total protein was immunoprecipitated (IP) with indicated antibody and samples were resolved by 10%
SDS-PAGE. Western blotting was done by stripping and reprobing the same membrane. Asterisks (*) indicate the immunoglobulin bands and poly-
(ub) indicates poly-ubiquitination.
doi:10.1371/journal.ppat.1001275.g002
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171–260) strongly associated with EBNA3C (Fig. 4C, top panel,
lanes 3, 4 and 6, respectively). However, no binding was detected
with the other truncated versions of Cyclin D1 (the CDK4/6
binding domain, residues 40–170 and the PEST domain, residues
241–295) or with the GST control (Fig. 4C, top panel, lanes 2, 5,
and 7). Importantly, the C-terminal domain of Cyclin D1 (residues
171–260) bound to EBNA3C with relatively higher affinity than
the full-length or the N-terminal site (Fig 4C).
In order to determine the specificity of EBNA3C and Cyclin D1
interaction, we next performed a co-immunoprecipitation assay
using all three flag-tagged D-type Cyclins. Interestingly, the results
showed that EBNA3C forms complexes with all three D-type
Cyclins in cells, suggesting that EBNA3C has specificity for
interaction with Cyclin D1, D2 and D3 (Fig. 4D).
EBNA3C can promote nuclear localization of Cyclin D1
Increased expression of Cyclin D1 has been seen in a number of
cancers [25,30]; however, this enhanced expression is usually not
sufficient to drive the oncogenic process. Emerging evidence
suggests that nuclear accumulation of Cyclin D1 resulting from
altered nuclear trafficking and proteolysis is critical for its
oncogenic phenotype [31]. In order to determine the effect of
EBNA3C on the sub-cellular localization of Cyclin D1, asynchro-
nously growing U2OS cells were transfected with expression
vectors encoding flag-tagged Cyclin D1 and GFP-tagged
EBNA3C. Localization of Cyclin D1 was determined by indirect
immunofluorescence using a monoclonal antibody against the flag
epitope (Fig. 5A, panels f, h, j, l). While Cyclin D1 mostly localized
to the cytoplasm in the absence of EBNA3C (Fig. 5A, panels f, h),
it was predominantly localized to the nucleus in the presence of
EBNA3C (Fig. 5A, panels j, l). To quantitatively compare the
Cyclin D1 signals in the nuclear and cytoplasmic compartments,
10 different fields of the stained slides were examined and the bar
diagram represents the mean of three independent experiments
which showed that nuclear localization was increased by 20%
(Fig. 5A, bar diagram). To further corroborate these results
showing that EBNA3C promotes nuclear localization of Cyclin
D1, the sub-cellular localization of endogenous Cyclin D1 was
determined in three different cell lines – EBV negative BL cell line
BJAB, BJAB cells stably expressing EBNA3C (E3C# 7) and an
EBV transformed B-cell line LCL2, using a specific antibody
against cyclin D1. As anticipated, the results showed that cyclin D1
was predominantly localized in the nucleus of both EBNA3C
positive BJAB cells (Fig. 5B, panels f, g) and EBV positive cells
LCL2 (Fig. 5B, panels j, k), but was almost exclusively cytoplasmic
in the EBV negative BJAB cells with no EBNA3C expressed
(Fig. 5B, panels b, c).
Based on immuno-fluorescence studies, we observed that Cyclin
D1 localization was mainly restricted to the cytoplasmic fraction of
asynchronously growing cells. However, on expression of
EBNA3C the localization of Cyclin D1 was predominantly
nuclear. To further support these data, transiently transfected
HEK 293 cells were subjected to sub-cellular fractionation and
fractionated proteins were analyzed by immunoblot analysis. The
result showed that flag-tagged Cyclin D1 alone was detected
approximately 50% in both cytoplasmic and nuclear fractions,
respectively (Fig. 6A, compare lanes 1 and 4). However, when co-
transfected with EBNA3C, flag-Cyclin D1 was detected predom-
inantly within the nuclear fraction (Fig. 6A, compare lanes 3 and
6), with an approximately 50% increase compared to flag-Cyclin
D1 alone (Fig. 6A, compare lanes 1 and 3). EBNA3C was detected
completely within nuclear fraction (Fig. 6A, lanes 2 and 3). The
efficiency of cytoplasmic and nuclear fractionation was confirmed
Figure 3. EBNA3C forms a complex with Cyclin D1 in human cells. A-B) 15 million HEK 293T cells were co-transfected with myc-tagged
EBNA3C and flag-tagged Cyclin D1 vectors. In each case control samples were balanced with empty vector. Cells were harvested at 36 h post-
transfection and approximately 5% of the lysed cells were saved as input and the residual lysate was immunoprecipitated (IP) with 1 mg of indicated
antibody. Lysates and IP complexes were resolved by 10% SDS-PAGE and western blotted (WB) with the indicated antibodies. C) 50 million BJAB cells
and two different clones of EBV transformed lymphoblastoid cell lines - LCL1 and LCL2, and in D) BJAB cells stably expressing EBNA3C (BJAB_E3C#10)
along with BJAB control cells were collected and lysed in RIPA buffer. Protein complexes were immunoprecipitated with Cyclin D1 specific antibody
and samples were resolved by a 10% SDS-PAGE followed by western blot with antibodies as indicated. E) Either GST control or GST-cyclin D1 beads
were incubated with lysates prepared from 50 million BJAB cells and two different clones of BJAB cells stably expressing EBNA3C (BJAB_E3C#7 and
#10). EBNA3C was detected by western blot with the specific monoclonal antibody (A10). Coomassie staining of a 12% SDS-PAGE resolved purified
GST and GST-Cyclin D1 proteins used in this study is shown in the right panel.
doi:10.1371/journal.ppat.1001275.g003
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protein GAPDH (Fig. 6A). These observations strongly suggested
that the apparent nuclear trans-localization of Cyclin D1 mediated
by EBNA3C, as determined by indirect immuno-fluorescence
microscopy or sub-cellular fractionation assay may be due to
deregulation of the critical regulatory kinase GSK-3b, a negative
regulator of Cyclin D1 nuclear retention and protein stability [31].
We thus decided to examine whether EBNA3C can nullify the
effect of GSK-3b on Cyclin D1 function.
EBNA3C blocks GSK3b dependent nuclear export of
Cyclin D1
GSK-3b can direct the nuclear export of Cyclin D1 via a
CRM1-dependent pathway [31]. To examine whether EBNA3C
can block Cyclin D1 nuclear export, we tested the ability of
EBNA3C to override GSK-3b triggered Cyclin D1 nuclear export.
To test this possibility, HEK 293 cells were transfected with
expression vectors encoding flag-tagged Cyclin D1, with or
without GSK-3b and myc-tagged EBNA3C. Fractionated cell
lysates were analyzed by western blot to clarify flag-tagged Cyclin
D1 localization. As expected, Cyclin D1 was primarily present in
the cytoplasmic fraction both in the absence and presence of GSK-
3b (Fig. 6B, lanes 1 and 4). In contrast, Cyclin D1 was largely
detected within the nuclear fraction when co-expressed with
EBNA3C (Fig. 6B, lane 3). Interestingly, even in the presence of
GSK-3b nuclear fractionation of Cyclin D1 was greatly increased
when co-expressed with EBNA3C compared with the vector
control (Fig. 6B, compare lanes 1 and 3).
GSK-3b has been shown to phosphorylate Cyclin D1 on Thr-
286 in vitro [31], and is postulated to be a major regulator of
protein levels and intracellular distribution of Cyclin D1 [31]. To
establish a plausible explanation for the inhibitory effects of
Figure 4. A small N-terminal region of EBNA3C binds to two different sites of Cyclin D1. A) 15 million HEK 293T cells were co-transfected
with vectors expressing flag-tagged Cyclin D1 and myc-tagged EBNA3C including full-length EBNA3C (residues 1-992) or different truncated mutants
(residues 1–365, 366–620 and 621–992), as indicated. Cells were harvested at 36 h and 5% of the lysed cells were saved as input and the residual
lysate was immunoprecipitated (IP) with 1 mg anti-myc antibody. Samples were resolved by 10% SDS-PAGE and transferred to 0.45 mm nitrocellulose
membrane. The membrane was probed with flag antibody to detect co-immunoprecipitated Cyclin D1. The membrane was stripped and reprobed
with anti-myc antibody to check the IP efficiency. B) Different truncated mutant constructs of EBNA3C (residues 1–100, 1–129, 1–159 and 1–200) were
in vitro translated using a T7-TNT translation kit. All S
35-radiolabeled in vitro translated proteins in binding buffer were precleared by rotating with
GST-beads for 1 h at 4uC. Binding reactions were setup by incubating the in vitro translated proteins with either GST control or GST-Cyclin D1
overnight. Reaction samples were resolved by 15% SDS-PAGE, exposed to phosphoimager plate and scanned on a Storm 850 imaging system. C) A
series of N- and C-terminal deletion mutants of GST-fused Cyclin D1 protein were purified and tested for their ability to bind in vitro translated S
35-
radiolabeled full-length EBNA3C as similar to (B). Coomassie staining of SDS-PAGE resolved purified GST proteins is shown in the bottom panel of (C).
D) 15 million HEK 293T cells were co-transfected with myc-tagged EBNA3C and either flag-tagged Cyclin D1, Cyclin D2 or Cyclin D3. Cells were
harvested at 36 h post-transfection and subjected to immunoprecipitation with 1 ug myc antibody. Lysates and IP complexes were resolved by 10%
SDS-PAGE and western blotted (WB) with the indicated antibodies. Asterisks (*) indicate the immunoglobulin bands.
doi:10.1371/journal.ppat.1001275.g004
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tion, we first asked whether EBNA3C can form a complex with
GSK-3b to negatively modulate its activity and to also determine
whether the kinase activity of GSK-3b is inhibited in the presence
of EBNA3C. To this end, we co-expressed myc-tagged GSK-3b
and flag-tagged EBNA3C and assessed their interaction through
co-immunoprecipitation experiment. The results showed that
indeed EBNA3C can form a complex with GSK-3b (Fig. 6C,
compare lanes 3 and 4). Next, an in vitro kinase assay was
conducted where GSK-3b was immuno-precipitated in the
absence and presence of EBNA3C, and tested for its ability to
phosphorylate recombinant GST-Cyclin D1 proteins (wild-type
and T286A mutant Cyclin D1). The results showed that the
phosphorylation level of wild-type GST-Cyclin D1 by GSK-3b
was reduced by more than 4 fold in the presence of EBNA3C
(Fig. 6D, compare lanes 1 and 2). As expected, no phosphorylation
bands were observed in case of mutant GST-Cyclin D1 (T286A)
indicating the specificity of this experiment (Fig. 6D, lanes 3 and
4). Parallel blots showed the protein expression levels in whole cell-
lysate (Fig. 6D), and the amount of purified GST-Cyclin D1 used
in this experiment (Fig. 6D). These results indicated that EBNA3C
may regulate Cyclin D1 sub-cellular localization probably by
blocking the function of GSK-3b.
EBNA3C enhances Cyclin D1-dependent kinase activity
To address the functional consequences as a result of the
association of Cyclin D1 and EBNA3C, we tested the activity of
Cyclin D1/CDK6 complexes for the ability to phosphorylate
histone H1 or recombinant GST-pRb (residues 792-928). HEK
293T cells were transiently transfected with increasing amounts of
a myc-tagged EBNA3C expression construct. Flag-tagged Cyclin
D1/CDK6 immunoprecipitated complexes were assayed for in
vitro kinase activity as determined by histone H1 or GST-pRb
phosphorylation (Fig. 7A and B, respectively). The results showed
that Cyclin D1-dependent kinase activity increased in a dose-
responsive manner with increased expression of EBNA3C (Fig. 7A
and B). Phosphorimager analysis revealed 1.6-times more P
32-
Histone H1 and 2.3-times more P
32-GST-pRb (Fig. 7A and B).
Figure 5. EBNA3C expression leads to an increase in nuclear retention of Cyclin D1. A) U2OS cells plated on coverslips and transiently
transfected with GFP-EBNA3C and flag-Cyclin D1 using Lipofectamine 2000. B) BJAB, BJAB cells stably expressing EBNA3C (BJAB_E3C#7) and an EBV
transformed lymphoblastoid cell line, LCL1 were plated and air-dried onto slides. Cells were fixed using a 1:1 mixture of acetone and methanol.
Ectopically and endogenously expressed Cyclin D1 was detected using M2-antibody (1:200 dilution) and DCS-6 (1:50 dilution) respectively, followed
by anti-mouse Alexa Fluor 594 (red). Endogenous EBNA3C in stable cell line and in EBV positive cells was detected using an EBNA3C-reactive rabbit
serum (1:150 dilution) followed by anti-rabbit Alexa Fluor 488 (green). The nuclei were counterstained using DAPI (49,69-diamidino-2-phenylindole).
The images were sequentially captured using an Olympus confocal microscope. In (A) the bar diagram represents the mean value of 10 different
fields of three independent experiments of Cyclin D1 cytoplasmic and nuclear localization.
doi:10.1371/journal.ppat.1001275.g005
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top two panels) and the amount of substrates (histone H1 or GST-
pRb) used in this study (Fig. 7A and B).
EBNA3C can reduce the half-life of pRb by regulating the
kinase activity of the cyclin D1/CDK6 complex
Cyclin D1/CDK4/6 complexes are rate-limiting for G1
progression by contributing to the sequential phosphorylation of
pRb, and thereby canceling the growth-suppressive function of
pRb, thus facilitating entry into S-phase [26,27]. Previously we
have shown that EBNA3C facilitates pRb degradation by
enhancing its poly-ubiquitination through recruitment of the
SCF
Skp2 E3 ligase activity [17]. To test whether EBNA3C coupled
with Cyclin D1/CDK6 complex regulates pRb stabilization, a
stability assay was performed using cycloheximide (CHX) treated
Saos-2 (pRb
-/- p53
-/-) cells co-transfected with plasmids expressing
myc-tagged pRb, flag-tagged Cyclin D1, flag-tagged CDK6, and
EBNA3C (Fig. 7C). The results clearly showed that independent
expression of either Cyclin D1/CDK6 complex or EBNA3C
reduced pRb expression levels (Fig. 7C [upper panel], compare
lanes 1-9). Surprisingly, when both EBNA3C and Cyclin D1/
CDK6 complex were expressed together, little or no pRb was
detected (Fig. 7C [lower panel], lanes 1-3), indicating that
EBNA3C can also facilitate pRb degradation in cooperation with
Cyclin D1/CDK6 either through stabilization of Cyclin D1
(Fig. 7C [lower panel], compare lanes 4–9) or increasing kinase
activity of Cyclin D1/CDK6 complex.
EBNA3C can enhance pRb ubiquitination in a Cyclin D1-
dependent manner
In order to probe whether EBNA3C enhances pRb poly-
ubiquitination in a Cyclin D1-dependent manner for degradation,
we performed an in vivo ubiquitination assay. HEK 293T cells were
co-transfected with expression constructs for myc-tagged pRb, HA-
tagged Ub, flag-tagged Cyclin D1 and CDK6 and untagged
EBNA3C as indicated (Fig. 7D). pRb was immunoprecipitated
with myc antibody, and ubiquitinated-pRb was detected by
probing blots with HA antibody. In agreement with the previous
Figure 6. EBNA3C bypasses GSK3b dependent nuclear export of Cyclin D1. A) 15 million HEK 293 cells were transiently co-transfected with
vectors of flag-tagged Cyclin D1 and myc-tagged EBNA3C and subjected to sub-cellular fractionation. Fractionated proteins were analyzed by
probing western blots with flag and myc antibodies. Nuclear protein Sp1 and cytoplasmic protein GAPDH were immuno-detected as control. B) As
similar to (A) 15 million HEK 293 cells were transfected with Cyclin D1 and different combinations of expression constructs as indicated and subjected
to sub-cellular fractionation. The fractionated proteins were analyzed by using indicated antibodies. The percent distribution of Cyclin D1 is shown as
numbers below panel (A) and (B). C) 15 million HEK 293T cells were co-transfected with myc-tagged GSK-3b and flag-tagged EBNA3C expression
vectors. Cells proteins were collected 36 h post-transfection and immunoprecipitated (IP) with 1 ug of flag antibody. Lysates and IP complexes were
resolved by 10% SDS-PAGE and western blotted (WB) with the indicated antibodies. Asterisk indicates the immunoglobulin bands. D) HEK 293T cells
were transfected with myc-tagged GSK-3b and flag-tagged EBNA3C vectors as indicated. Empty vector was used to balance total transfected DNA. At
36 h posttransfction, GSK-3b immunoprecipitates were captured with myc antibody and assayed for in vitro kinase activity toward either
recombinant GST-Cyclin D1 (lanes 1 and 2) or GST-Cyclin D1 T286 mutant (lanes 3 and 4) using cP
32-ATP. Western blot using whole cell lysates are
shown in first three panels and coomassie staining of SDS-PAGE resolved recombinant GST proteins used in this study is shown in panel 4.
doi:10.1371/journal.ppat.1001275.g006
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the presence of EBNA3C alone (Fig. 7D, compare lanes 3 and 4)
and slightly further elevated in the presence of both EBNA3C and
Cyclin D1/CDK6 complex (Fig. 7D, compare lanes 4 and 6)
indicating that EBNA3C together with Cyclin D1/CDK6 is
important for inducing pRb poly-ubiquitination and its subsequent
degradation.
EBNA3C nullifies the negative regulation of cell
proliferation by pRb
To determine the effect of EBNA3C and Cyclin D1/CDK6
complex on pRb mediated cell growth suppression, an osteosar-
coma cell line, Saos2, was transfected with the expression plasmids
for myc-tagged pRb, flag-tagged Cyclin D1, flag-tagged CDK6
and EBNA3C as indicated in the figure (Fig. 8A–D). Cells were
additionally transfected with a GFP expression vector. The cells
were selected with G418 for 2 weeks and the proliferation rate of
the selected cells was measured by an automated cell counter for 6
days (Fig. 8). Dead cells were excluded using Trypan Blue staining.
The rationale for choosing Saos2 as recipient cells was that cell
growth suppression and morphological changes can be observed in
Saos2 cells that express pRb de novo [48]. The results showed that
EBNA3C together with Cyclin D1/CDK6 complex effectively
reduced the growth suppressive effect of pRb. The cell-
proliferation rate of cells expressing pRb either with EBNA3C
Figure 7. EBNA3C enhances functional activity of Cyclin D1/CDK6 complex to negatively regulate pRb protein stability. A–B) Analysis
of Cyclin D1/CDK6 mediated phosphorylation of Histone H1 and pRb. HEK 293T cells were transfected with flag-tagged Cyclin D1 and CDK6 vectors
and 0, 5, or 15 mg of myc-tagged EBNA3C vector. 36 h post-transfection, flag immunoprecipitates were captured and assayed for in vitro kinase
activity on (A) Histone H1 or (B) recombinant GST-pRb (residues 792-928) as similar to figure 6D. C) Stability assay of pRb. Saos-2 (pRb
-/-) cells were co-
transfected with expression plasmids for myc- tagged pRb, flag-tagged Cyclin D1 and CDK6, and EBNA3C. 36 h post-transfection, cells were treated
with 40 mg/ml cycloheximide (CHX) for the indicated times. Samples were resolved by SDS-PAGE. GAPDH was immunodetected to normalize protein
levels. Western blots were probed with the indicated antibodies. D) Ubiquitination of pRb. HEK 293T cells were transfected with expression plasmids
for myc-tagged pRb, HA-tagged ubiquitin (Ub), and EBNA3C (E3C), and flag-tagged Cyclin D1/CDK6 as indicated. Cells were harvested at 36 h, and
total protein was immunoprecipitated (IP) with myc-specific antibody. Samples were resolved by SDS-PAGE. Western blots were probed with the
indicated antibodies.
doi:10.1371/journal.ppat.1001275.g007
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alone (Fig. 8A). However, interestingly EBNA3C together with
Cyclin D1/CDK6 complex significantly enhanced the cell
proliferation rate, which was approximately either 6 fold higher
than pRb alone or 3 fold higher than pRb when co-expressed with
either EBNA3C or Cyclin D1/CDK6 complex (Fig. 8A). To check
the expression levels of these proteins, the selected cells were
subjected to western blot analysis (Fig. 8B). The results showed
that the pRb expression levels were significantly reduced in
EBNA3C or Cyclin D1/CDK6 expressing samples, whereas no
changes of expression were observed for other proteins (Fig. 8B).
GAPDH was used as an internal loading control and expression of
GFP indicated equivalent amount of total protein lysate prepared
from selected cells (Fig. 8B).
In order to corroborate the previous experiment, we next
performed a colony formation assay, where cells were similarly
transfected with different combinations of expression constructs as
stated above. After selection of the transfected cells with G418
similarly as stated above for 2 weeks, the number of antibiotic-
resistant colonies was counted (Fig. 8C–D). In agreement with the
previous experiment, the results showed that co-expression of both
EBNA3C and Cyclin D1/CDK6 proteins with pRb in Saos-2 cells
resulted in an increase in the number of colonies compared to pRb
alone (Fig. 8C, compare panels 1–3 and Fig. 8D, bar diagram).
However, interestingly EBNA3C together with Cyclin D1/CDK6
complex markedly increased the antibiotic-resistant colonies
(Fig. 8C, compare panels 1-4 and Fig. 8D, bar diagram). Overall,
these results indicate that EBNA3C can utilize the function of
Cyclin D1/CDK6 to neutralize the growth inhibitory effect of
pRb.
EBNA3C and Cyclin D1 are required for cell-cycle
progression in EBV transformed cells
In the context of the above-described results, we hypothesized
that EBNA3C exploits Cyclin D1/CDK6 to promote LCL
proliferation by inactivating pRb. To address this, LCLs were
stably transduced with lentiviruses that express short hairpin RNA
to silence either EBNA3C (Sh-E3C) or cyclin D1 (Sh-CyD1). The
Sh-Control RNA is not complementary to human genome
sequences. Stable transduction was verified by GFP expression
(Fig. 9A). The expression levels of knocked down genes among
these cells were then detected by Western blot analysis (Fig. 9B).
The results showed that the level of EBNA3C or Cyclin D1 was
knocked down by sh-RNA whereas LCL1 transduced with sh-
Figure 8. EBNA3C coupled with Cyclin D1/CDK6 complex nullifies the growth suppressive effect by pRb. A-B) Saos-2 cells were
transfected with expression plasmids for myc-tagged pRb, flag-tagged Cyclin D1 and CDK6 and EBNA3C. Cells were additionally transfected with GFP
expression vector. Cells were selected for 2 weeks with G418. A) Approximately 0.1610
6 cells from each set of samples were plated into each well of
the 6-well plates and cultured for 6 days. Viable cells from each well were counted by trypan blue exclusion method daily using an automated cell
counter. For (B) 5610
6 cells were harvested, lysed in RIPA buffer and subjected for immunoblot analyses using indicated antibodies. C–D) Saos-2 cells
transfected with different combinations of expression plasmids as described in panel (A) and selected similarly as stated above with G418. After a 2-
week selection, cells were fixed on the plates with 4% formaldehyde and stained with 0.1% crystal violet. The area of stained cells in each dish was
calculated by Image J software. A and D) The bar diagram represents the average data of two independent experiments with standard deviation.
doi:10.1371/journal.ppat.1001275.g008
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showed that pRb expression levels were slightly increased in both
EBNA3C and Cyclin D1 knocked down samples, whereas there
were no alterations observed for other Cyclin D expression levels
(Fig. 9B). In order to determine whether both EBNA3C and
Cyclin D1 are critical to maintain the proliferation of EBV
transformed cells, a proliferation analysis was done (Fig. 9C). The
results showed that the proliferation rate of both wild-type LCL1
and LCL1 infected with the lentivirus control sh-RNA (Sh-
Control) expressing physiological level of both EBNA3C and
Cyclin D1 was significantly higher than that of LCLs with Sh-E3C
and Sh-CyD1 (Fig. 9C). In agreement with the previously
published results [20,49], we also observed that the proliferation
rate of LCLs containing Sh-E3C with reduced levels of EBNA3C
expression was approximately 3 fold slower than that of control
cell-lines (Fig. 9C). Interestingly, the proliferation rate of LCLs
with Sh-CyD1 was 50% higher than LCLs with Sh-E3C and only
about 1.5 fold lower than that of control. This suggests that other
D-type cyclins might be involved in LCL growth, particularly
Cyclin D2 which was shown earlier to be associated in EBV
mediated lymphomagenesis and probably transcriptionally up-
regulated by one of the other major EBV latent antigen LMP1
[45]. However, it is clear from repeated analyses that cyclin D1
knock-down correlates with an increase in doubling time. The
results support the notion that EBNA3C and cyclin D1 are critical
for driving the growth of EBV transformed cells.
It has been shown earlier that both EBV positive cells and cells
stably expressing EBNA3C can bypass G1/S phase checkpoint
caused by serum starvation [20,35]. Cell-cycle profiles of cells
cultured in medium with 0.1% FBS were analyzed by flow
cytometry (Fig. 10). Analyses of serum-starved, EBV negative cell
lines BJAB and DG75 and LCLs sh-E3C and sh-CyD1 revealed
an increased percentage of cells at the G0/G1 phase of the cell
cycle (Fig. 10A, B) and decreased percentage of cells in the G2/M
phases (Fig.10A, C). Fig. 10B and 10C represents the difference in
both G0/G1 and G2/M phases due to serum starvation,
respectively. However, under the same culture conditions, the
EBV-positive LCLs - LCL1, LCL2, LCL1-with Sh-control and
BJAB-cells stably expressing EBNA3C (E3C# 7 and E3C# 10)
continued through the cell-cycle without being arrested at any
particular phase (Fig. 10A histograms, B and C). Furthermore, the
results also indicated that upon knockdown of both EBNA3C and
Cyclin D1, LCLs underwent a substantial degree of apoptosis (Sub
G0) in response to serum starvation, similar to EBV negative cell
lines, BJAB and DG75 (Fig. 10A). However, there was no sign of
apoptosis observed either in BJAB cells stably expressing EBNA3C
or wild-type LCLs (Fig. 10A). Altogether, this experiment
demonstrated that EBNA3C and Cyclin D1 positively contribute
Figure 9. Both EBNA3C and Cyclin D1 are required for cell-cycle progression in EBV transformed cells. (A) Lentivirus transduced short
hairpin RNA vectors knock down EBNA3C and Cyclin D1 in EBV transformed LCLs. Transduction with sh-RNA-containing lentivirus and selection of
EBV-infected cells (LCL1) with puromycin resulted in stable cell lines expressing specific si-RNA against EBNA3C (LCL1_sh-E3C), cyclin D1 (LCL1_sh-
CyD1) and sh-RNA sequence that lacks any complementary sequences in the human genome (LCL1_sh-Cont). The selected cells with GFP
fluorescence were monitored by fluorescent microscopy. (B) Western blots showing the expression levels of EBNA3C, pRb, Cyclin D1, Cyclin D2 and
Cyclin D3 in LCLs. GAPDH was used as the loading control. (C) Approximately 1 million cells were plated into each well of the 6-well plates and
cultured at 37uC in complete medium without puromycin. Viable cells from each well were counted by trypan blue exclusion method daily for twenty
days using an automated cell counter. The results shown are representative of two independent experiments. Error bars show standard deviations.
doi:10.1371/journal.ppat.1001275.g009
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overriding the G1 block as a result of serum starvation.
Discussion
The cyclin D1 gene amplification has been observed in cancers of
the breast, head and neck or larynx [50,51,52]. Chromosomal
rearrangement is another cause of Cyclin D1 over-expression
associated with centrocytic lymphomas [53], parathyroid adeno-
mas [54] and mantle cell lymphoma [28]. The obvious association
of Cyclin D1 with cancer has led the investigators to uncover its
oncogenic properties. In fact, Cyclin D1 was shown to cooperate
with the Ras oncoprotein for cell transformation [55].
Earlier reports have suggested that immortalization of primary
B-lymphocytes by EBV is accompanied by transcriptional
activation of the cyclin D2 gene but not cyclin D1 [43,44,45].
However, a number of studies showed noticeable changes in
Cyclin D1 protein levels in both EBV positive LCLs [35] and EBV
positive SCID mice lymphomas [37]. Despite the controversy
regarding the Cyclin D1 expression in EBV positive B-lymphoma
cells, it is clear that in order to deregulate the entire mammalian
cell-cycle, EBNA3C manipulates G1 restriction point through
disruption of Cyclin/CDK-pRb-E2F pathway [20].
Cyclin D1 is over-expressed in a variety of human cancers that
do not exhibit cyclin D1 gene amplification or structural
abnormalities of the cyclin D1 locus, which suggests that increased
Cyclin D1 stability is a potential mechanism. Mutations of cyclin
D1 at T286 and P287 have been found in human tumors [24] and
alter Cyclin D1 nuclear localization as well as stability. Our data
showed that both EBV infection in primary B-cells and EBV
persistence in cancer cell lines increased protein stability. However
the cyclin D1 mRNA level was unchanged. Similar to virus
Figure 10. EBNA3C and Cyclin D1 are critical for G1 to S phase progression. A) Cells were grown for 12 h in RPMI medium containing 10%
FBS (+ serum) or 0.1% FBS (- serum). Propidium iodide stained cells were analyzed by flow cytometry. The bar diagram represents the change in cell-
cycle profile either in (B) G0-G1 phase or (C) G2-M phase due to serum starvation of cells. The results shown are representative of two independent
experiments.
doi:10.1371/journal.ppat.1001275.g010
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without altering mRNA levels. It is important to determine if these
effects also occur in vivo.
The results presented here also demonstrated that the
expression of Cyclin D2 and D3 were up-regulated in quiescent
cells infected with EBV probably through distinctly different
mechanisms. EBV infection or its transforming protein latent
membrane protein 1 (LMP1) up-regulates Cyclin D2 expression in
primary B-lymphocytes and Burkitt’s lymphoma cells [45]. None
of the studies have shown an important role for Cyclin D3 in EBV-
mediated cell transformation. Studies have suggested that the D-
type cyclins may have non-overlapping functions at specific steps
in B-cell differentiation [32], and that the expression of different
D-type cyclins may be influenced by EBV infection through
distinctive pathways. Thus, a potential mechanism which involves
the contribution of Cyclin D1 in EBV-mediated B-cell transfor-
mation is the constitutive induction of these key cell-cycle
regulators which leads to pRb hyper-phosphorylation and
uncontrolled cell proliferation.
Several lines of evidence suggest that Cyclin D1 is targeted by
the E3 ligase, SCF
FBX4-aB crystallin for degradation [26]. Elevated
expression of FBX4 and aB crystallin is also found to trigger the
destruction of wild-type Cyclin D1, but not the phosphorylation-
deficient Cyclin D1 mutant, D1T286A [26]. Thus, impairment of
SCF
FBX4-aB crystallin function may also account for Cyclin D1
overexpression. Data from the ubiquitination assay showed that
EBNA3C efficiently inhibits Cyclin D1 poly-ubiquitination, which
led us to speculate that EBNA3C may interact with this particular
E3 ligase and inhibit its ability to ubiquitinate Cyclin D1. The
SCF
Skp2 ligase has also been shown to be involved in the
degradation of Cyclin D1 [56,57,58], and knockdown of Skp2
molecule promoted marked accumulation of Cyclin D1 [57].
EBNA3C interacts with SCF components to regulate the stability
of p27
KIP1 and pRb [12,17]. It is likely EBNA3C inhibition of
SCF
Skp2 reduces Cyclin D1 ubiquitination. EBNA3C may be a
deubiquitinase or associate with one to regulate the stability of
Mdm2 [18] and likely Cyclin D1. Since the expression level of
Cyclin D1 is related to the potential for malignancy and the
prognosis of a variety of cancers [30,31], revealing the mechanisms
governing the ubiquitin-proteasome mediated degradation of
Cyclin D1 is of importance in designing therapeutic interventions.
Conceivably, this approach could amplify the therapeutic window
using Cyclin D1 as a target and enhance the efficacy of
conventional drugs against EBV mediated oncogenesis.
We have shown earlier that EBNA3C can interact with Cyclin
D1 using an in vitro GST-pulldown experiment [16]. Here, we
examined the molecular association between EBNA3C and Cyclin
D1 complexes to obtain a more in-depth understanding of the
different domains of EBNA3C that modulate the activity of Cyclin
D1 which will lead to further understanding the basic mechanism
by which EBV regulates the mammalian cell-cycle. EBNA3C
associates with Cyclin D1 via the same N-terminal domain,
residues 130-190, that has been shown to bind many critical cell-
cycle regulators [18] including other Cyclins - A and E [16]. In
addition, a recent genetic study using recombinant EBV
expressing conditionally active EBNA3C showed that deletion of
this particular domain could not support cell proliferation of EBV
transformed LCLs, signifying the importance of this domain
within EBNA3C [49]. The association of EBNA3C with different
Cyclins suggests is perhaps cell-cycle dependent and one may
replace another depending on the stage in the cell-cycle, which
ultimately leads to aberrant cell proliferation in EBV transformed
cells. The previously published data and the data herein were
generated using asynchronously growing cells; therefore it would
be interesting to further elucidate these interactions in a cell-cycle
dependent manner. However, using chemical synchronization is
likely to distort the true activities underlying EBNA3C function
with Cyclin complexes. Nevertheless, we will be undertaking this
line of experimentation in the near future.
To promote G1-S phase transition, nuclear localization of
Cyclin D1 is critical and it occurs either via decreased proteolysis
in cytoplasm which facilitates nuclear import or through inhibition
Figure 11. A schematic illustration of how EBNA3C regulates Cyclin D1 stability and functions to facilitate G1 to S phase transition
in EBV positive cells. In EBV transformed cells, EBNA3C forms a complex with Cyclin D1 and augments its stability through inhibiting poly-
ubiquitination and blocking GSK3b activity. EBNA3C further enhances the kinase activity of Cyclin D1/CDK6 complex and recruits its activity to
facilitate the ubiquitination and subsequent degradation of hyperphosphorylated form of pRb, which in turn releases E2F transcription factor from an
inhibitory constraint and enables the expression of genes required for entry into the S phase.
doi:10.1371/journal.ppat.1001275.g011
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ylation at T286 [27,59]. Immunofluorescent studies showed that
EBNA3C expression enforces nuclear localization of Cyclin D1.
Increased stability and nuclear accumulation of Cyclin D1 in the
presence of EBNA3C prompted us to examine whether EBNA3C
can also negatively regulate GSK-3b function linked to the
stability of Cyclin D1. Indeed, our data show that EBNA3C forms
a complex with GSK-3b and significantly reduces its kinase
activity toward Cyclin D1, thereby enhancing the nuclear
retention of Cyclin D1. Altogether, these data suggest that either
by increasing nuclear import by blocking the poly-ubiquitination
level of Cyclin D1 or inhibiting nuclear export of Cyclin D1 via
inhibiting the kinase activity of its negative regulator GSK-3b,
EBNA3C would likely ensure the efficient nuclear accumulation of
Cyclin D1 during G1-phase. However, we cannot eliminate the
possibility that EBNA3C may also facilitate Cyclin D1 nuclear
accumulation through additional strategies.
Cyclin D1 is central to the coordination of the cell-cycle
progression at the G1 to S phase transition by integrating the
control of pRb phosphorylation with the transcriptional activity of
E2F [60]. Cyclin D1 in association with its binding partner, CDK4
or 6 phosphorylates pRb to facilitate S phase entry [60]. Previously
we have shown that EBNA3C enhances the kinase activity of
Cyclin A/CDK2 complex [15] and recruits an E3 ligase SCF
Skp2
to degrade pRb [17]. Similarly, here we show that by an in vitro
kinase assay EBNA3C increases the activity of Cyclin D1/CDK6
complex toward both Histone H1 and a truncated mutant of pRb.
Moreover, EBNA3C in conjunction with Cyclin D1/CDK6
complex increases pRb poly-ubiquitination and thereby enhances
its degradation process. In addition, we show EBNA3C coupled
with Cyclin D1/CDK6 complex significantly abolishes the growth
suppressive function of pRb in Saos-2 cells.
Studies using serum starved conditions have shown that both
EBV and its essential nuclear antigen, EBNA3C can bypass G1
restriction point probably through disruption of Cyclin/CDK-
pRb-E2F pathway [21,36]. LMP1 has also been shown to be
associated with resistance to G1 arrest during serum starvation
[36]. Taking advantage of these findings, together with the use of
sh-RNA mediated gene knockdown strategies, we have generated
knockdown lymphoblastoid cell-lines targeting both EBNA3C and
cyclin D1 transcripts and assayed for cellular proliferation to
carefully determine the plausible role of both of these viral and
cellular oncoproteins. Indeed, our results show that both EBNA3C
and Cyclin D1 are critical for efficient proliferation of EBV
infected B-cells. Moreover, the results point out that upon
knockdown of these gene products, cells undergo significant
apoptosis, probably through induction of the activities of the
tumor suppressors – p53 and pRb. Earlier results [14] and the data
herein adequately show that EBNA3C critically regulates the
growth suppressive properties of both p53 and pRb.
Overall, we have shown in this report that the essential EBV
latent antigen, EBNA3C physically interacts with and stabilizes
Cyclin D1 by blocking nuclear export or inhibiting the poly-
ubiquitination. In addition, EBNA3C alters pRb phosphorylation
as well as stability by enhancing Cyclin D1/CDK6 kinase activity,
thereby nullifying pRb mediated growth suppressive activity
(Fig. 11). Furthermore, knockdown of both EBNA3C and Cyclin
D1 expression by lentivirus-delivered sh-RNA demonstrated that
both EBNA3C and Cyclin D1 play a critical role in cell
proliferation in EBV transformed cells. Thus, the present study
provides an insight into the mechanisms linked to the development
of EBV-associated B-cell lymphomas through the enhancement of
a major cell-cycle component, Cyclin D1, which is known to
orchestrate the activities of a vast range of cellular networks that
are important in the development of human cancers.
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